Atrial fibrillation

Developing new solutions with iRhythm for improved screening, monitoring and management of patients with AFib

What is the AFib program?

We’re collaborating with iRhythm to develop solutions aimed at improving the screening, monitoring, and management of patients with atrial fibrillation (AFib). AFib is the most common type of irregular heart rhythm, and can lead to blood clots, stroke, heart failure and other heart-related complications. Millions of patients in the U.S. today live with undiagnosed AFib. New, clinically integrated and user-friendly solutions could provide an early detection system to help identify and manage patients that may have otherwise gone undiagnosed until they had a significant cardiac event, such as a stroke.

How are you making it happen?

This collaboration extends our work developing health management solutions for people with pre-existing conditions. We are combining capabilities with iRhythm, such as continuous monitoring, data analytics and cloud-based machine learning, to create innovative solutions for screening and monitoring AFib. Our product and engineering teams are focused on technical integrations and exploring how we can leverage tools like Study Watch with ECG and Irregular Pulse Monitor and iRhythm’s Zio Service to support continuous monitoring. We aim to create a clinical solution that takes into account clinician workflows, care pathways and the patient experience. Together, we are exploring ways to enhance technology not only for monitoring and management, but for earlier intervention, and where possible, prevention.